Since oncogenic alterations that aberrantly activate RAS/RAF/MEK/ERK signaling mainly occur on RAFs, particularly BRAF or upstream, this family of kinases has been considered an ideal target for cancer drug development. The gene discussed is MAPK1; the disease is cancer.